Volume 16 Issue 2, April 2019
Conducting clinical trials—costs, impacts, and the value of clinical trials networks: A scoping review
Colene Bentley, Sonya Cressman, Kim van der Hoek, Karen Arts, Janet Dancey, Stuart Peacock
First Published January 10, 2019; pp. 183–193
Key findings from the review are: 1) delayed trial activation has costs to budgets and research; 2) poor accrual leads to low-value trials and wasted resources; 3) the pharmaceutical industry can be a pragmatic, if problematic, partner in clinical research; 4) organizational know-how and successful research collaboration are benefits of network/cooperative groups; and 5) there are spillover benefits of clinical trials to healthcare systems, including better health outcomes, enhanced research capacity, and drug cost avoidance. There is a need for more economic evaluations of the benefits of clinical research, such as health system use (or avoidance) and health outcomes in cities and health authorities with institutions that conduct clinical research, to demonstrate the affordability of clinical trials, despite their high cost.